7Baggers
 Published on: 2025-10-03 01:48:18  newser.com Fri, 03 Oct 2025 06:48:18 GMT
 published on: 2025-10-02 20:22:21  newser.com Fri, 03 Oct 2025 01:22:21 GMT
 published on: 2025-10-02 19:47:12  newser.com Fri, 03 Oct 2025 00:47:12 GMT
 Revolution Medicines, Inc. (RVMD) Insider Sells Shares  Yahoo Finance Thu, 02 Oct 2025 13:45:26 GMT
 published on: 2025-10-01 05:45:46  newser.com Wed, 01 Oct 2025 10:45:46 GMT
 Revolution Medicines hires Mirati, ALX vet Sandler  BioCentury Tue, 30 Sep 2025 23:43:00 GMT
 revolution medicines shows improved relative strength; still shy of benchmark  Investor's Business Daily Tue, 30 Sep 2025 07:00:00 GMT
 Revolution Medicines appoints new chief development officer By Investing.com  Investing.com Nigeria Tue, 30 Sep 2025 05:42:57 GMT
 Revolution Medicines Stock Soars Amid Strategic Moves  TipRanks Mon, 29 Sep 2025 16:05:49 GMT
 Published on: 2025-09-29 09:01:49  newser.com Mon, 29 Sep 2025 14:01:49 GMT
 Revolution Medicines appoints new chief development officer  Investing.com Mon, 29 Sep 2025 13:29:49 GMT
 Revolution Medicines appoints Alan Sandler as CDO  TipRanks Mon, 29 Sep 2025 13:25:07 GMT
 Published on: 2025-09-29 04:07:09  newser.com Mon, 29 Sep 2025 09:07:09 GMT
 published on: 2025-09-29 02:11:50  newser.com Mon, 29 Sep 2025 07:11:50 GMT
 published on: 2025-09-28 21:32:25  newser.com Mon, 29 Sep 2025 02:32:25 GMT
 Cislini Jeff, general counsel at Revolution Medicines, sells $79,623 in stock  Investing.com Nigeria Fri, 26 Sep 2025 22:02:16 GMT
 strs ohio makes new investment in revolution medicines, inc. $rvmd  MarketBeat Tue, 23 Sep 2025 08:56:15 GMT
 wedbush predicts reduced earnings for revolution medicines  MarketBeat Sat, 20 Sep 2025 00:52:08 GMT
 wedbush reduces earnings estimates for revolution medicines  MarketBeat Fri, 19 Sep 2025 07:00:00 GMT
 wedbush predicts reduced earnings for revolution medicines  MarketBeat Fri, 19 Sep 2025 04:26:09 GMT
 wedbush predicts lower earnings for revolution medicines  MarketBeat Fri, 19 Sep 2025 04:26:09 GMT
 q3 eps estimates for revolution medicines reduced by wedbush  MarketBeat Thu, 18 Sep 2025 03:37:16 GMT
 wedbush cuts earnings estimates for revolution medicines  MarketBeat Wed, 17 Sep 2025 08:25:28 GMT
 revolution medicines (nasdaq:rvmd) price target raised to $73.00  MarketBeat Wed, 17 Sep 2025 07:00:00 GMT
 what is wedbush's estimate for rvmd fy2029 earnings?  MarketBeat Wed, 17 Sep 2025 07:00:00 GMT
 revolution medicines (nasdaq:rvmd) price target raised to $73.00  MarketBeat Tue, 16 Sep 2025 22:52:30 GMT
 wedbush equities analysts cut earnings estimates for rvmd  MarketBeat Tue, 16 Sep 2025 05:12:09 GMT
 q3 eps estimates for revolution medicines reduced by wedbush  MarketBeat Tue, 16 Sep 2025 05:12:09 GMT
 revolution medicines exec kelsey sells $5.5m in shares  Investing.com Tue, 16 Sep 2025 02:27:48 GMT
 Revolution Medicines exec Kelsey sells $5.5m in shares  Investing.com Mon, 15 Sep 2025 07:00:00 GMT
 wedbush research analysts lower earnings estimates for rvmd  MarketBeat Sun, 14 Sep 2025 11:13:02 GMT
 revolution medicines (nasdaq:rvmd) price target raised to $77.00  MarketBeat Sat, 13 Sep 2025 12:54:19 GMT
 revolution’s daraxonrasib data bolster phase iii case amid ras cancer push  insights.citeline.com Fri, 12 Sep 2025 20:51:24 GMT
 revolution medicines resumed with a strong buy at raymond james  TipRanks Fri, 12 Sep 2025 10:38:58 GMT
 td cowen maintains revolution medicines(rvmd.us) with buy rating  富途牛牛 Thu, 11 Sep 2025 14:31:00 GMT
 Revolution’s daraxonrasib moves to Phase III after PDAC hat-trick  Clinical Trials Arena Thu, 11 Sep 2025 07:00:00 GMT
 revolution medicines’ surging potential: what’s happening?  StocksToTrade Thu, 11 Sep 2025 07:00:00 GMT
 revolution medicines stock skyrockets: what’s next?  timothysykes.com Thu, 11 Sep 2025 07:00:00 GMT
 revolution medicines reports promising phase 1 study results  TipRanks Wed, 10 Sep 2025 07:00:00 GMT
 revolution medicines reports promising pancreatic cancer drug results  Investing.com Wed, 10 Sep 2025 07:00:00 GMT

Revolution Medicines, Inc
(NASDAQ:RVMD) 

RVMD stock logo

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gyne...

Founded: 2014
Full Time Employees: 117
CEO: Mark A. Goldsmith  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends